Ionis Pharmaceuticals, Inc. (IONS)
After hours:
| Previous Close | 30.01 |
| Open | 29.70 |
| Bid | 29.07 x 800 |
| Ask | 31.10 x 1400 |
| Day's Range | 29.45 - 30.69 |
| 52 Week Range | 25.04 - 64.37 |
| Volume | |
| Avg. Volume | 1,141,108 |
| Market Cap | 4.219B |
| Beta (5Y Monthly) | 0.90 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -4.37 |
| Earnings Date | Feb. 22, 2022 - Feb. 28, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 51.19 |
- Zacks
Ionis' (IONS) Partner to Begin New Huntington's Disease Study
Ionis' (IONS) partner, Roche, is planning a new phase II study to evaluate tominersen for the treatment of Huntington's disease.
- Zacks
Biogen (BIIB) Opts for In-Licensing SMA Therapy From Ionis
Biogen (BIIB) exercises its option to acquire a royalty-bearing license from Ionis to develop and commercialize BIIB115/ION306 for treating spinal muscular atrophy.
- GlobeNewswire
Biogen Exercises Option with Ionis to Develop and Commercialize Investigational ASO for SMA
BIIB115 is a preclinical investigational antisense oligonucleotide (ASO) that may have the potential for extended dosing intervalsBiogen paid Ionis a $60 million one-time upfront payment CAMBRIDGE, Mass. and CARLSBAD, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that Biogen exercised its option to obtain from Ionis a worldwide, exclusive, royalty-bearing license to develop and commercialize BIIB115/ION306. The
